Rapamycin
Human evidence and active trials are visible in this field
97 human-evidence records · 28 active trials · 194 visible funding records · 6,773 universities
Longevity Patent Family
Nano-composite for delivering rapamycin based on targeted peptide modified gold nanoparticles as well as preparation method and application of nano-composite
Source-linked patent metadata for Nano-composite for delivering rapamycin based on targeted peptide modified gold nanoparticles as well as preparation method and application of nano-composite, including priority, record stage and longevity-topic connections.
Patent-family snapshot
Application publication visible
Family grouping brings related publications for the same invention together, instead of counting every national filing as a separate technology.
- Representative publication
- CN121370824A
- Earliest priority
- November 28, 2025
- Latest publication
- January 23, 2026
- Family publications
- 1
- Patent offices
- 1
Patent-to-Evidence Translation Map
What is happening in the same scientific field?
These connections share a longevity topic with this patent record. They do not prove that the listed evidence, trials, funders, or universities validate, finance, own, or support this invention.
Organizations named in this family
Topics connected by metadata
Rapamycin88% metadata match
What this family cites
- Earlier patent references
- 0
- Scientific and other non-patent references
- 0
- Priority dates represented
- 1
References show which earlier documents the patent record points to. They do not validate the invention or prove that cited research supports its claims.
How the patent office classifies this invention
No patent classification is available in the retained record.
Verify in the original patent source →